Shopping Cart

Your shopping cart is currently empty

NXT629

Name: NXT629
Brand: TargetMol
SKU: T12278
Price: 189 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T12278Cas No. 1454925-59-7

Alias NXT 629

NXT629 is a selective and highly efficient PPAR-α antagonist with anticancer activity. It inhibits PPARδ, PPARγ, Erβ, GR, and TRβ and can be used in research on ovarian cancer and melanoma.

NXT629

Copy Product Info

😃Good

Purity: 99.07%

Catalog No. T12278Alias NXT 629Cas No. 1454925-59-7

NXT629 is a selective and highly efficient PPAR-α antagonist with anticancer activity. It inhibits PPARδ, PPARγ, Erβ, GR, and TRβ and can be used in research on ovarian cancer and melanoma.

Pack Size	Price	USA Warehouse	Global Warehouse	Quantity
1 mg	$189	-	In Stock
5 mg	Preferential	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.07%

Appearance:Solid

Color:White to Yellow

Resource Download

COA

Product Introduction

Bioactivity

Description	NXT629 is a selective and highly efficient PPAR-α antagonist with anticancer activity. It inhibits PPARδ, PPARγ, Erβ, GR, and TRβ and can be used in research on ovarian cancer and melanoma.
Targets&IC50	ERβ:15.2 μM, PPARγ (human):15 μM, PPARα (human):77 nM, GR:32.5 μM, PPARδ (human):6 μM
In vitro	NXT629 (compound 33) is a potent and selective PPAR-α antagonist with an IC50 of 77 nM for human PPARα, as well as weaker effects on other nuclear hormone receptors (e.g., PPARδ, PPARγ, Erβ, GR, and TRβ) with IC50s of 6.0 μM, 15 μM, 15.2 μM, 32.5 μM, and >100 μM, respectively.[1] The competitive inhibitory ability of NXT629 on PPARα, PPARβ/δ and PPARγ was also validated, with corresponding IC50s of 2.3 μM, 35.1 μM and 6.9 μM, respectively.[2]
In vivo	NXT629 exhibits low oral bioavailability in mice and rats. NXT629 administered intraperitoneally (30 mg/kg once daily for 6 weeks) significantly slowed down the growth of subcutaneous SKOV-3 tumors in nude mice and showed inhibition of subcutaneous B16F10 tumor growth in C57Bl/6 mice. In addition, NXT629 (30 mg/kg, intraperitoneal injection) showed weak anti-angiogenic activity in FGF-induced angiogenesis. NXT629 (3 and 30 mg/kg, intraperitoneal injection) also reduced experimental metastasis of B16F10 melanoma cells in the lungs of mice. [2]
Synonyms	NXT 629

Chemical Properties

Molecular Weight	609.78
Formula	C₃₅H₃₉N₅O₃S
Cas No.	1454925-59-7
Smiles	O=C1N(N=C(N1CC)CCCC=2C=CC(=CC2)C3=NC=C(C=C3)NS(=O)(=O)C=4C=CC=CC4)CC5=CC=C(C=C5)C(C)(C)C
Relative Density.	1.20 g/cm3 (Predicted)

Storage & Solubility Information

Storage

store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 100 mg/mL (163.99 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (6.56 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.6399 mL	8.1997 mL	16.3994 mL	81.9968 mL
5 mM	0.3280 mL	1.6399 mL	3.2799 mL	16.3994 mL
10 mM	0.1640 mL	0.8200 mL	1.6399 mL	8.1997 mL
20 mM	0.0820 mL	0.4100 mL	0.8200 mL	4.0998 mL
50 mM	0.0328 mL	0.1640 mL	0.3280 mL	1.6399 mL
100 mM	0.0164 mL	0.0820 mL	0.1640 mL	0.8200 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc